St Luke's International Hospital, Kidney Center, Akashi-cho 9-1, Chuo-ku, Tokyo, Japan.
Miyazaki Clinic, Nagasaki, Japan.
Clin Exp Nephrol. 2023 Sep;27(9):717-727. doi: 10.1007/s10157-023-02360-y. Epub 2023 Jun 6.
Encapsulating peritoneal sclerosis (EPS), a condition with a high mortality rate, is a serious complication of peritoneal dialysis (PD). In Japan, EPS became a central issue in the clinical setting during the mid-90s and the beginning of this century. However, following the introduction of biocompatible neutral PD solutions containing lower levels of glucose degradation products, the incidence and clinical severity of EPS has been greatly lessened. During the past three decades, the etiology of EPS has been elucidated by findings obtained by peritoneal biopsy, laparoscopy, and surgical intervention. Accumulating findings suggest the need for a paradigm change on the nature of EPS pathophysiology; notably, EPS appears not to reflect peritoneal sclerosis per se, but rather the formation of a neo-membrane as a biological reaction to peritoneal injury. This narrative review looks back on the history of EPS in Japan, and discusses EPS pathophysiology, the impact of neutral PD solution on peritoneal protection, and a future novel diagnostic approach, ultra-fine endoscope, for the identification of patients at high risk of EPS.
包裹性腹膜硬化症(EPS)是一种死亡率较高的疾病,是腹膜透析(PD)的严重并发症。在日本,EPS 在 90 年代中期和本世纪初成为临床中的一个核心问题。然而,随着含有较低葡萄糖降解产物的生物相容性中性 PD 溶液的引入,EPS 的发病率和临床严重程度大大降低。在过去的三十年中,通过腹膜活检、腹腔镜检查和手术干预获得的结果阐明了 EPS 的病因。越来越多的研究结果表明,需要对 EPS 病理生理学的性质进行范式转变;值得注意的是,EPS 似乎并不反映腹膜本身的硬化,而是作为对腹膜损伤的生物反应形成新的膜。本综述回顾了日本 EPS 的历史,并讨论了 EPS 的病理生理学、中性 PD 溶液对腹膜保护的影响,以及未来一种用于识别高风险 EPS 患者的新型诊断方法——超细内镜。